Nutritional therapies in congenital disorders of glycosylation (CDG)

Peter Witters, David Cassiman, Eva Morava-Kozicz

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

Congenital disorders of glycosylation (CDG) are a group of more than 130 inborn errors of metabolism affecting N-linked, O-linked protein and lipid-linked glycosylation. The phenotype in CDG patients includes frequent liver involvement, especially the disorders belonging to the N-linked protein glycosylation group. There are only a few treatable CDG. Mannose-Phosphate Isomerase (MPI)-CDG was the first treatable CDG by high dose mannose supplements. Recently, with the successful use of D-galactose in Phosphoglucomutase 1 (PGM1)-CDG, other CDG types have been trialed on galactose and with an increasing number of potential nutritional therapies. Current mini review focuses on therapies in glycosylation disorders affecting liver function and dietary intervention in general in N-linked glycosylation disorders. We also emphasize now the importance of early screening for CDG in patients with mild hepatopathy but also in cholestasis.

Original languageEnglish (US)
Article number1222
JournalNutrients
Volume9
Issue number11
DOIs
StatePublished - Nov 1 2017
Externally publishedYes

Fingerprint

Congenital Disorders of Glycosylation
diet therapy
glycosylation
Glycosylation
Lipid-Linked Proteins
Therapeutics
Galactose
Phosphoglucomutase
Inborn Errors Metabolism
galactose
Liver
Cholestasis
mannose-6-phosphate isomerase
Mannose
inherited metabolic diseases
phosphoglucomutase
cholestasis
Phosphates
liver function
mannose

Keywords

  • Congenital disorders of glycosylation (CDG)
  • Diet
  • Galactose
  • Glycosylation
  • Mannose
  • Treatment

ASJC Scopus subject areas

  • Food Science
  • Nutrition and Dietetics

Cite this

Nutritional therapies in congenital disorders of glycosylation (CDG). / Witters, Peter; Cassiman, David; Morava-Kozicz, Eva.

In: Nutrients, Vol. 9, No. 11, 1222, 01.11.2017.

Research output: Contribution to journalReview article

Witters, Peter ; Cassiman, David ; Morava-Kozicz, Eva. / Nutritional therapies in congenital disorders of glycosylation (CDG). In: Nutrients. 2017 ; Vol. 9, No. 11.
@article{64bba2e76cb74b748996d61bb3dc77f9,
title = "Nutritional therapies in congenital disorders of glycosylation (CDG)",
abstract = "Congenital disorders of glycosylation (CDG) are a group of more than 130 inborn errors of metabolism affecting N-linked, O-linked protein and lipid-linked glycosylation. The phenotype in CDG patients includes frequent liver involvement, especially the disorders belonging to the N-linked protein glycosylation group. There are only a few treatable CDG. Mannose-Phosphate Isomerase (MPI)-CDG was the first treatable CDG by high dose mannose supplements. Recently, with the successful use of D-galactose in Phosphoglucomutase 1 (PGM1)-CDG, other CDG types have been trialed on galactose and with an increasing number of potential nutritional therapies. Current mini review focuses on therapies in glycosylation disorders affecting liver function and dietary intervention in general in N-linked glycosylation disorders. We also emphasize now the importance of early screening for CDG in patients with mild hepatopathy but also in cholestasis.",
keywords = "Congenital disorders of glycosylation (CDG), Diet, Galactose, Glycosylation, Mannose, Treatment",
author = "Peter Witters and David Cassiman and Eva Morava-Kozicz",
year = "2017",
month = "11",
day = "1",
doi = "10.3390/nu9111222",
language = "English (US)",
volume = "9",
journal = "Nutrients",
issn = "2072-6643",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "11",

}

TY - JOUR

T1 - Nutritional therapies in congenital disorders of glycosylation (CDG)

AU - Witters, Peter

AU - Cassiman, David

AU - Morava-Kozicz, Eva

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Congenital disorders of glycosylation (CDG) are a group of more than 130 inborn errors of metabolism affecting N-linked, O-linked protein and lipid-linked glycosylation. The phenotype in CDG patients includes frequent liver involvement, especially the disorders belonging to the N-linked protein glycosylation group. There are only a few treatable CDG. Mannose-Phosphate Isomerase (MPI)-CDG was the first treatable CDG by high dose mannose supplements. Recently, with the successful use of D-galactose in Phosphoglucomutase 1 (PGM1)-CDG, other CDG types have been trialed on galactose and with an increasing number of potential nutritional therapies. Current mini review focuses on therapies in glycosylation disorders affecting liver function and dietary intervention in general in N-linked glycosylation disorders. We also emphasize now the importance of early screening for CDG in patients with mild hepatopathy but also in cholestasis.

AB - Congenital disorders of glycosylation (CDG) are a group of more than 130 inborn errors of metabolism affecting N-linked, O-linked protein and lipid-linked glycosylation. The phenotype in CDG patients includes frequent liver involvement, especially the disorders belonging to the N-linked protein glycosylation group. There are only a few treatable CDG. Mannose-Phosphate Isomerase (MPI)-CDG was the first treatable CDG by high dose mannose supplements. Recently, with the successful use of D-galactose in Phosphoglucomutase 1 (PGM1)-CDG, other CDG types have been trialed on galactose and with an increasing number of potential nutritional therapies. Current mini review focuses on therapies in glycosylation disorders affecting liver function and dietary intervention in general in N-linked glycosylation disorders. We also emphasize now the importance of early screening for CDG in patients with mild hepatopathy but also in cholestasis.

KW - Congenital disorders of glycosylation (CDG)

KW - Diet

KW - Galactose

KW - Glycosylation

KW - Mannose

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85033464792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85033464792&partnerID=8YFLogxK

U2 - 10.3390/nu9111222

DO - 10.3390/nu9111222

M3 - Review article

VL - 9

JO - Nutrients

JF - Nutrients

SN - 2072-6643

IS - 11

M1 - 1222

ER -